Shares of Xencor, Inc. (XNCR) are spiking over 13% in early market trading Thursday, after the company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today reported top-line results from a Phase 1b/2a study for XmAb5871. Xencor said the study showed promising activity in patients with rheumatoid […]
View the full post at: Morning Buzz: Xencor (XNCR), Vivus (VVUS), Yahoo (YHOO), Alibaba Group (BABA), Venaxis (APPY)